The Efficacy and Safety of Anlotinib Plus Etoposide with Cisplatin/Carboplatin in the First-Line Treatment of Lung Cancer: A Phase II Clinical Study

This phase II clinical study evaluated the safety and efficacy of combining anlotinib with etoposide and platinum-based drugs as a first-line treatment for extensive small-cell lung cancer (ES-SCLC). The study reported a disease control rate (DCR) of 97.6% and an objective response rate (ORR) of 91.0%. The estimated progression-free survival (PFS) was 5.0 months, and overall survival (OS) was 13.0 months. Common adverse reactions included anemia, hypertension, and alopecia, with 35.56% of cases experiencing grade 3-5 adverse events. No treatment-related deaths occurred. The combination therapy showed promising outcomes and prognosis for ES-SCLC management.